Dec 6 2022 |
MEI Pharma Announces Adjournment of Annual Meeting of Stockholders |
PDF |
Dec 5 2022 |
MEI Pharma Initiates Strategic Realignment |
PDF |
Dec 5 2022 |
MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting |
PDF |
Nov 18 2022 |
Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan |
PDF |
Nov 14 2022 |
MEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational Highlights |
/sites/meipharma-corp/files/2022-11/meip-q1-2023-fiscal-earnings-final.pdf
|
Nov 3 2022 |
MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022 |
PDF |
Oct 3 2022 |
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
PDF |
Sep 22 2022 |
MEI Pharma Announces Changes to Board of Directors |
PDF |
Sep 8 2022 |
MEI Pharma Reports Fiscal Year 2022 Results and Operational Highlights |
/sites/meipharma-corp/files/2022-09/meip-2022-earnings-release-final.pdf
|
Sep 6 2022 |
MEI Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022 |
PDF |
Sep 1 2022 |
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
PDF |
Sep 1 2022 |
MEI Pharma to Release 2022 Fiscal Year End Financial Results and Provide Corporate Update on September 8, 2022 |
PDF |
Aug 1 2022 |
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
PDF |
Jul 18 2022 |
MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy |
PDF |
Jul 1 2022 |
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
PDF |
Jun 22 2022 |
MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer |
PDF |
Jun 10 2022 |
MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress |
PDF |
Jun 4 2022 |
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022 |
PDF |
Jun 1 2022 |
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
PDF |
May 26 2022 |
MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022 |
PDF |
May 23 2022 |
MEI Pharma Reports Third Quarter Fiscal Year 2022 Results and Operational Highlights |
/sites/meipharma-corp/files/meip-q3-2022-fiscal-earnings.pdf
|
May 17 2022 |
MEI Pharma to Present at the H.C. Wainwright Global Investment Conference 2022 |
PDF |
May 12 2022 |
MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress |
PDF |
May 2 2022 |
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
PDF |
Apr 8 2022 |
MEI Pharma Announces Two Presentations at the American Association for Cancer Research Annual Meeting 2022 |
PDF |
Apr 1 2022 |
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
PDF |
Mar 24 2022 |
MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA |
/sites/meipharma-corp/files/2022-03/zandelisib-fda-update-march2022-final.pdf
|
Mar 8 2022 |
MEI Pharma Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 |
PDF |
Mar 1 2022 |
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
PDF |
Feb 10 2022 |
MEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational Highlights |
/sites/meipharma-corp/files/meip-q2-2022-fiscal-earnings.pdf
|
Feb 7 2022 |
MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments |
PDF |
Jan 3 2022 |
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
PDF |